Alzamend Neuro, Inc. (ALZN) Form S-1 — Aug 21, 2026

$ALZNForm S-1Filed Aug 21, 2026, 4:30 PM ET0001214659-26-010726Original filing

Alzamend Neuro filed an S-1 registering the resale of up to 98,388,305 shares of common stock by Ault Lending, LLC, consisting of conversion shares issuable upon conversion of 25,000 shares of Series D Convertible Preferred Stock sold under a $25 million committed equity financing agreement dated July 31, 2026.

Key figures

Gross Proceeds: Up to $25,000,000 to the company from Series D preferred sales; $0 from the registered resales
Shares Offered: 98388305
Shares Outstanding: 4,825,723 pre-offering; 103,214,028 pro forma after full conversion
Second Closing: $2,500,000
Initial Closing: $7,500,000
Liquidated Damages: 2% monthly, capped at 15%
Nasdaq Limit Shares: 964662
Sec Registration Fee: $20,347.17
Pre Deal Closing Price: $1.35 (Jul 30, 2026)
Conversion Floor Price: $0.2668
Monthly Closing Amount: $1,000,000
Last Reported Sale Price: $1.63 (Aug 20, 2026)
Beneficial Ownership Cap: 4.99% (increaseable to 9.99%)
Conversion Maximum Price: $2.00
Total Estimated Expenses: $70,347
Max Aggregate Offering Price: $147,336,486.74
Stated Value Per Preferred Share: $1,050

Price after filing

1 day: -4.3%7 days: +1.8%30 days: +16.0%

Close on the filing date to close N calendar days later (from $1.63). Historical, not a forecast.

AI analysis

Red flags9 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.